Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016 in Advanced Malignant Solid Tumors
NCT06592417Phase 1Recruiting
- Sponsor
- Alphamab Oncology
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JSKN016 in solid tumor, sponsored by Alphamab Oncology. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events, Treatment-Related Adverse Events, Serious Adverse Events and 2 more. Started Apr 2024; status: recruiting.
02
Drugs
JSKN016
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06592417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592417.